Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
Illumina launched its first distributed whole-genome sequencing solution for molecular residual disease (MRD) research, targeting solid tumors and blood cancers. The workflow, built on the NovaSeq X platform, offers 10 ppm sensitivity and 99.5% specificity, with a turnaround time of five days. It is currently in early access for select partners, including Mayo Clinic, with a global commercial launch planned for next year.
Key figures
- Workflow turnaround
- 5 days
- Analytical sensitivity
- 10 ppm
- Analytical specificity
- 99.5%
- Novaseq x active install base
- 890
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.